Emblem Corp is a Canada-based Company engaged in alternative medicine sector. The Company is producer and distributor of medical cannabis and cannabis derivatives licensed under the Access to Cannabis for Medical Purposes Regulations (ACMPR). The Company operates in one segment, the production and sale of medical cannabis to patients who have received medical authorizations to acquire and use cannabis. The Company offers fully integrated services covering the full cannabis spectrum, from growing to selling, as well as educating and also creating new forms of cannabinoid-based medication in standardized dosages. All of the Companyâ€™s assets are located in Canada.

Employees

Sector

Pharmaceuticals

More about the company

Select your edition

All financial news and data tailored to specific country editions

NORTH AMERICA

United-States

Canada

End-of-day quote Toronto S.E. Other stock markets 01:29:45 19/03/2019 am IST			5-day change	1st Jan Change
1.880 ^CAD	+1.62%		+1.62%	+106.59%

15/19/15	Emblem Corp. Reports Earnings Results for the Full Year Ended December 31, 2018	CI
19/19/19	Emblem Corp.(TSXV:EMC) dropped from S&P/TSX Venture Composite Index	CI

Market Cap	25Cr 22Cr 20Cr 19Cr 35Cr 2.38TCr 36Cr 241.55Cr 94Cr 1.18TCr 93Cr 91Cr 4.06TCr	P/E 2017	-16.3x	P/E 2018	-4.48x
Enterprise Value	22Cr 19Cr 18Cr 16Cr 31Cr 2.1TCr 31Cr 213.29Cr 83Cr 1.04TCr 82Cr 81Cr 3.59TCr	EV / Sales 2017	7,23,52,077x	EV / Sales 2018	1,09,15,686x
Free-Float	98.36%	Yield 2017 *	-	Yield 2018	-

15/19/15	Emblem Corp. Reports Earnings Results for the Full Year Ended December 31, 2018	CI
19/19/19	Emblem Corp.(TSXV:EMC) dropped from S&P/TSX Venture Composite Index	CI
14/19/14	Aleafia Health Inc. completed the acquisition of Emblem Corp..	CI
07/19/07	Emblem Corp. Announces Amended By-Laws; Announces Change to the Registered Office	CI
19/18/19	Emblem Corp., Aleafia Health Inc. - M&A Call
19/18/19	Aleafia Health Inc. executed a letter of intent to acquire Emblem Corp. for approximately CAD 160 million.	CI
10/18/10	Emblem Corp Announces Executive Appointments	CI
20/18/20	Emblem Corp. Appoints Wayne Kreppner as Division President	CI
20/18/20	Emblem Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2018	CI
07/18/07	Emblem Corp. Announces Board Changes	CI
11/18/11	Emblem Bolsters Medical Division to Support Growth and Product Innovation with Appointment of Wayne Kreppner as President	CI
30/18/30	10330698 Canada Ltd. announced that it has received CAD 1 million in funding from Emblem Corp.	CI
24/18/24	DriveABLE Assessment Centres Inc. announced that it has received funding from Emblem Corp.	CI

Manager	Title	Age	Since
Tricia Symmes CEO	Chief Executive Officer	-	-
Nick Dean CEO	Chief Executive Officer	-	01/12/2017
Ethan Karayannopoulos IRC	Investor Relations Contact	-	-

Emblem Corp Share Price

Stocks

EMC

CA29082J1084

Pharmaceuticals

Valuation: Emblem Corp

Latest news : Emblem Corp

Press Releases: Emblem Corp

Quotes and Performance

Managers and Directors: Emblem Corp

Alternative Medicine

Financials

Company Profile

Director	Title	Age	Since
John H. Stewart BRD	Director/Board Member	-	-
Jeffrey Fineberg BRD	Director/Board Member	-	-
Terry Johnson BRD	Director/Board Member	-	06/12/2016

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
EMBLEM CORP	+1.62%	+1.62%	-	-	0
YUNNAN BAIYAO GROUP CO.,LTD	+0.24%	-0.58%	-9.57%	-4.79%	1.34TCr
BEIJING TONGRENTANG CO., LTD	+1.48%	-2.34%	-29.89%	-50.71%	507.59Cr
DONG-E-E-JIAO CO., LTD.	+1.81%	+3.33%	+1.61%	+3.33%	479.57Cr
SHIJIAZHUANG YILING PHARMACEUTICAL CO., LTD.	+2.07%	+1.45%	+4.23%	-32.06%	404.66Cr
TIANJIN PHARMACEUTICAL DA REN TANG GROUP CORPORATION LIMITED	+1.01%	-2.45%	+2.41%	-8.01%	363.24Cr
HUBEI JUMPCAN PHARMACEUTICAL CO., LTD.	+1.09%	+2.67%	-0.99%	-3.09%	362.89Cr
TASLY PHARMACEUTICAL GROUP CO., LTD	+1.02%	+3.51%	-1.67%	+10.63%	347.73Cr
SHANDONG BUCHANG PHARMACEUTICALS CO., LTD.	+3.04%	+2.25%	-11.86%	-22.31%	240.47Cr
HENAN LINGRUI PHARMACEUTICAL CO., LTD.	+1.92%	-0.31%	-3.42%	+42.77%	182.23Cr
Average	+1.53%	-0.56%	-5.46%	-7.14%	423.23Cr
Weighted average by Cap.	+1.18%	-0.71%	-6.87%	-9.79%

	2017	2018
Net sales	2.69 2.37 2.2 2.02 3.8 258.35 3.85 26.2 10.23 127.57 10.11 9.9 440.92	8.22 7.23 6.73 6.18 11.6 788.58 11.76 79.99 31.24 389.39 30.87 30.2 1.35T
Net income	-1.21Cr -1.06Cr -99.03L -90.94L -1.71Cr -116.05Cr -1.73Cr -12Cr -4.6Cr -57Cr -4.54Cr -4.44Cr -198.06Cr	-2.43Cr -2.13Cr -1.99Cr -1.82Cr -3.42Cr -232.64Cr -3.47Cr -24Cr -9.22Cr -114.87Cr -9.11Cr -8.91Cr -397.04Cr
Net Debt	-2.15Cr -1.89Cr -1.76Cr -1.62Cr -3.04Cr -206.3Cr -3.08Cr -21Cr -8.17Cr -101.87Cr -8.08Cr -7.9Cr -352.08Cr	-2.91Cr -2.55Cr -2.38Cr -2.18Cr -4.1Cr -278.62Cr -4.15Cr -28Cr -11Cr -137.58Cr -11Cr -11Cr -475.51Cr